THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN) said Friday that the European Commission or EC has approved a new indication for Prolia, or denosumab, for the treatment of bone loss associated with lo...
More From BioPortfolio on "Amgen: EC Approves Prolia For Patients With Glucocorticoid-Induced Osteoporosis"